Jazz Pharmaceuticals said it sold a priority review voucher to an undisclosed company for $200 million, landing the highest price for such a voucher since 2016.
Jazz will take home half …
Read More from Endpoints News
Jazz sells priority review voucher for $200M, scoring highest price in a decade
